CJC-1295 vs Tesamorelin
How they differ
- FDA status. CJC-1295: Unapproved new drug in cited enforcement record.1 Tesamorelin: FDA-approved as Egrifta for HIV-associated abdominal fat.2,3
- Kinds of studies cited. CJC-1295: smaller controlled human trials. Tesamorelin: large randomized human trials. How these labels are assigned
Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.
Side by side
| Topic | CJC-1295 | Tesamorelin |
|---|---|---|
| What it is | A synthetic analogue of growth hormone-releasing hormone, 29 amino acids long. A version with an added drug affinity complex (DAC) binds to albumin in the blood and lasts longer.4 | A growth hormone-releasing factor (GHRF) analogue. The label states that it binds to and stimulates human GRF receptors with potency similar to the natural hormone.2 |
| FDA status | Not FDA-approved Unapproved new drug in cited enforcement record1 Not FDA-approved. FDA staff recommended in 2024 against adding any CJC-1295-related substance to the 503A compounding list, and FDA lists CJC-1295 among compounding substances that may present significant safety risks.4,5 | FDA-approved FDA-approved as Egrifta for HIV-associated abdominal fat2,3 FDA-approved. Drugs@FDA lists Egrifta (first approved November 10, 2010), and the label covers reducing excess abdominal fat in adults with HIV and lipodystrophy. The cited label has no boxed warning.2,3 |
| HHS compounding policy, October 30, 2026 | Not among the six peptides the policy lists.6 HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. CJC-1295 is not among them.6,7 | Not among the six peptides the policy lists.6 |
| FDA compounding safety-risk page | Listed. FDA’s compounding safety-risk page, current as of April 22, 2026, lists CJC-1295 among substances whose nominations were withdrawn, citing possible immune reactions, impurities and serious adverse events including increased heart rate.5 | Not addressed in this profile’s sources. |
| Kinds of studies cited | Smaller controlled human trials
|
|
| Records collected | 11 ClinicalTrials.gov records and 21 PubMed records collected | |
| Area of study | ||
| Latest dated events |
|
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1Nicholasville Compounding Pharmacy and Its Owner Plead Guilty to Unlawful Distribution of Prescription Drugs ↗
U.S. Department of Justice · Official source · Source checked July 22, 2026
- 2EGRIFTA SV (tesamorelin) kit · SPL version 9 · published 2026-07-31 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked September 15, 2026
- 3Drugs@FDA application BLA022505 · original submission status AP · 2010-11-10 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 4FDA evaluation of five CJC-1295-related bulk substances, November 15, 2024 ↗
U.S. Food and Drug Administration · Official source · Source checked September 15, 2026
- 5Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 6HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 7Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 8Federal Register notice 2024-24828 · published 2024-10-25 · Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List ↗
Federal Register via GovInfo · Official source · Source checked August 21, 2026